Final draft guidance published by Nice shows NHS England requested that Mounjaro is rolled out over a period of 12 years. The ...

However the NHS spending watchdog has announced Mounjaro will only be given to 220,000 people in England during the first three years - despite 3.4 million people being eligible for it. Trials have ...

Fewer than one in ten patients who meet the criteria for Mounjaro will be given it by the health service over the next three ...

Britain's drugs cost-effectiveness watchdog NICE said on Thursday it will recommend Eli Lilly's obesity drug Mounjaro be made available to around 220,000 people in the country via the state health ...

Following its endorsement of Eli Lilly’s obesity medicine tirzepatide, England’s National Institute for Health and Care ...

However, Dr Kath McCullough, NHS England’s national speciality adviser for obesity, warned that weight loss jabs “are not a ...

Lilly said patients taking Zepbound lost about 20% of their weight on average compared with nearly 14% for Wegovy. The drug ...

The rise of weight loss drugs is not only changing individual lives, but also reshaping large sections of the economy.

More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.